Captrust Financial Advisors Allakos Inc. Transaction History

Captrust Financial Advisors

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	SELL	$2.6 - $6.14 $179 - $423	-69 Reduced 8.53%	740 $2,000
Q1 2022 May 16, 2022	BUY	$5.08 - $9.81 $4,003 - $7,730	788 Added 3752.38%	809 $5,000
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $34 - $447	4 Added 23.53%	21 $0
Q3 2021 Nov 16, 2021	SELL	$76.53 - $110.43 $688 - $993	-9 Reduced 34.62%	17 $2,000
Q2 2021 Aug 16, 2021	SELL	$85.37 - $114.1 $256 - $342	-3 Reduced 10.34%	26 $2,000
Q1 2021 May 17, 2021	BUY	$109.73 - $153.66 $3,182 - $4,456	29 New	29 $3,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.